Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma

Serba, Susanne; Schmidt, Jan; Wentzensen, Nicolas; Ryschich, Eduard; Märten, Angela

doi:10.1136/gut.2007.130252

Cited by 23 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Signaling via CD40 activates antigen-presenting cells both in vitro and in vivo . 1–3 CD40 ligation on dendritic cells induces cellular maturation and activation as detected by increased surface expression of co-stimulatory and major histocompatibility complex molecules, production of proinflammatory cytokines, such as interleukin 12, and enhanced T-cell activation. 1 CD40 ligation of resting B cells increases antigen-presenting function and induces proliferation and immunoglobulin class switching.…”

Section: Introductionmentioning

confidence: 99%

Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression

Melo‐Cardenas¹,

Urquiza²,

Kipps

et al. 2012

Cancer Gene Ther

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression

Melo‐Cardenas¹,

Urquiza²,

Kipps

et al. 2012

Cancer Gene Ther

View full text Add to dashboard Cite

“…Animal Model Male C57BL/6 mice (Charles River) were kept and treated in accordance with the principles laid down in Orthotopic injection was done as described previously (34). Therapy was started 5 days after pancreatic tumor cell inoculation.…”

Section: Cell Lines and Treatment Schemementioning

confidence: 99%

Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma

Märten

Zeiss²,

Serba³

et al. 2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

The purpose of the present study was to evaluate the potency of the proteasome inhibitor bortezomib F gemcitabine in vitro and in vivo in pancreatic carcinoma. It could be shown that bortezomib induced apoptosis and inhibited proliferation of pancreatic carcinoma very efficiently in vitro. In contrast, in an orthotopic pancreatic adenocarcinoma mouse model, gemcitabine treatment inhibited tumor growth, whereas bortezomib promoted it. Bortezomib-treated animals showed significantly higher tumor burden compared with gemcitabine-treated and control animals, although bortezomib was locally active and induced a decrease of proteasome activity, which was most pronounced following the simultaneous administration of gemcitabine. Also, tumor progression was not caused by immunosuppression as a result of proteasome inhibition. Interestingly, anti-CD31 staining of tumors showed that angiogenesis was significantly increased in the tumors of bortezomib-treated mice compared with the tumors of control animals. In addition, bortezomib resulted an increase of pericytes, vascular endothelial growth factor, RGS-5, and hypoxia-inducible factor-1A in the tumor. Although this study supports efficacy of bortezomib against pancreatic carcinoma in vitro, it strongly indicates that bortezomib therapy has a significant tumorpromoting effect in vivo by induction of angiogenesis. The data are in accordance with the complete failure of bortezomib in a phase II trial for this indication. Choosing the right schedule of gemcitabine and bortezomib showed some synergistic effects, but the gain might not be big enough to compensate the potentially detrimental effects.

show abstract

“…Similar attenuation of tumor growth in gastrointestinal tumors, such as pancreatic carcinomas, has been achieved following CD40 ligand gene therapy (Serba et al, 2008;Kuhlmann et al, 2008). CD40 ligand gene transfection by using adenoviruses has also been successfully used for regressing tumor growth in pulmonary carcinomas (Wu et al, 2007).…”

mentioning

confidence: 87%

Growing role of CD40 ligand gene transfer therapy in the management of systemic malignancies besides hepatocellular carcinomas

Kapoor

2009

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Transfection with CD40L induces tumour suppression by dendritic cell activation in an orthotopic mouse model of pancreatic adenocarcinoma

Abstract: The induction of anti-tumour activity initiated after treating mice with the CD40L plasmid was achieved. Further investigations showed that this is mediated by mature myeloid dendritic cells which activate CD8 cells. Clinical trials investigating CD40L-based therapies should be extended.

Cited by 23 publications

References 21 publications

Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression

Intratumoral delivery of CD154 homolog (Ad-ISF35) induces tumor regression: analysis of vector biodistribution, persistence and gene expression

Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma

Growing role of CD40 ligand gene transfer therapy in the management of systemic malignancies besides hepatocellular carcinomas

Contact Info

Product

Resources

About